A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price

A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price

Source: 
Stat
snippet: 

Studies in thousands of people on multiple continents now show the malaria drug hydroxychloroquine does not help patients hospitalized with Covid-19 live longer. But on Tuesday the White House, based on a new study that outsiders greeted with deep skepticism, disagreed.